NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

CompletedPhase 1

Sponsor: Carmot Australia First Pty Ltd

Conditions: Type 2 Diabetes, Overweight or Obesity

Interventions: CT-996, Placebo

Countries: Australia, Mexico

This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants 18-65 years old, inclusive
* BMI of 25 - 40, inclusive
* Stable body weight for two months

Additional Inclusion Criterion for Part 3 (MD T2DM cohorts) only:

* Participants in Part 3 should have a documented diagnosis of Type 2 Diabetes Mellitus (T2DM)
* Participants in Part 3 should have glycated hemoglobin (HbA1c) between 7.0% and 10.0%

Exclusion Criteria:

* History of significant medical conditions and malignancy
* Uncontrollable hypertension
* History of alcoholism or drug addiction within 1 year prior to Screening
* Current or recent participation in an investigational clinical trial

Locations (2)

Melbourne, Australia
San Pedro Garza García, Mexico